Concepts (98)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intraabdominal Infections | 9 | 2025 | 9 | 2.000 |
Why?
|
| Cross Infection | 3 | 2025 | 7 | 1.360 |
Why?
|
| Anti-Bacterial Agents | 5 | 2025 | 43 | 1.000 |
Why?
|
| Candidiasis | 1 | 2025 | 1 | 0.950 |
Why?
|
| Antimicrobial Stewardship | 4 | 2025 | 5 | 0.900 |
Why?
|
| Female | 16 | 2025 | 984 | 0.840 |
Why?
|
| Humans | 21 | 2025 | 1907 | 0.800 |
Why?
|
| Medical Order Entry Systems | 4 | 2025 | 4 | 0.740 |
Why?
|
| Adult | 12 | 2025 | 554 | 0.570 |
Why?
|
| Pregnancy Complications, Infectious | 7 | 2024 | 8 | 0.560 |
Why?
|
| Male | 9 | 2025 | 1055 | 0.530 |
Why?
|
| Middle Aged | 7 | 2025 | 494 | 0.490 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 6 | 2025 | 8 | 0.480 |
Why?
|
| Nursing Homes | 3 | 2025 | 4 | 0.440 |
Why?
|
| Pregnancy | 8 | 2024 | 44 | 0.440 |
Why?
|
| Long-Term Care | 2 | 2025 | 4 | 0.390 |
Why?
|
| Aged | 8 | 2025 | 418 | 0.390 |
Why?
|
| Child | 7 | 2024 | 157 | 0.370 |
Why?
|
| Anti-Infective Agents, Local | 2 | 2024 | 2 | 0.370 |
Why?
|
| United States | 6 | 2024 | 157 | 0.310 |
Why?
|
| Skin | 2 | 2025 | 11 | 0.280 |
Why?
|
| Diagnostic Imaging | 5 | 2024 | 11 | 0.280 |
Why?
|
| Hospitalization | 5 | 2025 | 22 | 0.260 |
Why?
|
| Infection Control | 2 | 2024 | 5 | 0.260 |
Why?
|
| Chlorhexidine | 3 | 2024 | 4 | 0.240 |
Why?
|
| Whole Genome Sequencing | 1 | 2025 | 1 | 0.240 |
Why?
|
| Phylogeny | 1 | 2025 | 1 | 0.240 |
Why?
|
| Genome, Fungal | 1 | 2025 | 1 | 0.240 |
Why?
|
| Genomics | 1 | 2025 | 4 | 0.240 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2025 | 1 | 0.240 |
Why?
|
| Chicago | 1 | 2025 | 56 | 0.230 |
Why?
|
| Soft Tissue Infections | 1 | 2025 | 10 | 0.230 |
Why?
|
| Blood Culture | 1 | 2024 | 1 | 0.220 |
Why?
|
| Cholangitis | 1 | 2024 | 1 | 0.220 |
Why?
|
| Abdominal Abscess | 1 | 2024 | 1 | 0.220 |
Why?
|
| Cholecystitis, Acute | 1 | 2024 | 1 | 0.220 |
Why?
|
| Appendicitis | 1 | 2024 | 3 | 0.220 |
Why?
|
| Diverticulitis | 1 | 2024 | 4 | 0.220 |
Why?
|
| Urinary Tract Infections | 1 | 2024 | 2 | 0.220 |
Why?
|
| Health Facilities | 1 | 2024 | 3 | 0.220 |
Why?
|
| Bacterial Infections | 1 | 2024 | 2 | 0.220 |
Why?
|
| Pneumonia | 1 | 2024 | 6 | 0.220 |
Why?
|
| Reimbursement, Incentive | 1 | 2024 | 2 | 0.210 |
Why?
|
| Candida | 1 | 2023 | 1 | 0.200 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2019 | 4 | 0.190 |
Why?
|
| Staphylococcal Infections | 2 | 2019 | 7 | 0.190 |
Why?
|
| Aged, 80 and over | 3 | 2025 | 210 | 0.160 |
Why?
|
| Disinfection | 1 | 2019 | 1 | 0.150 |
Why?
|
| Mupirocin | 1 | 2019 | 1 | 0.150 |
Why?
|
| Acute Disease | 2 | 2024 | 20 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2024 | 37 | 0.110 |
Why?
|
| California | 2 | 2024 | 9 | 0.090 |
Why?
|
| Administration, Intranasal | 2 | 2024 | 3 | 0.090 |
Why?
|
| Bacteria | 1 | 2025 | 1 | 0.060 |
Why?
|
| Metagenomics | 1 | 2025 | 1 | 0.060 |
Why?
|
| Microbiota | 1 | 2025 | 1 | 0.060 |
Why?
|
| beta-Lactamases | 1 | 2025 | 3 | 0.060 |
Why?
|
| Bacterial Proteins | 1 | 2025 | 5 | 0.060 |
Why?
|
| Hospitals, Community | 1 | 2024 | 1 | 0.050 |
Why?
|
| Pneumonia, Bacterial | 1 | 2024 | 1 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 59 | 0.050 |
Why?
|
| Length of Stay | 1 | 2024 | 8 | 0.050 |
Why?
|
| Iodophors | 1 | 2024 | 1 | 0.050 |
Why?
|
| Universal Precautions | 1 | 2024 | 1 | 0.050 |
Why?
|
| Skin Care | 1 | 2024 | 1 | 0.050 |
Why?
|
| Baths | 1 | 2024 | 2 | 0.050 |
Why?
|
| Patient Transfer | 1 | 2024 | 3 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2024 | 4 | 0.050 |
Why?
|
| Hospitals | 1 | 2024 | 13 | 0.050 |
Why?
|
| Benchmarking | 1 | 2024 | 2 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2024 | 7 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 95 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2023 | 9 | 0.050 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2019 | 1 | 0.040 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2019 | 2 | 0.040 |
Why?
|
| Vancomycin-Resistant Enterococci | 1 | 2019 | 2 | 0.040 |
Why?
|
| Public Health | 1 | 2019 | 6 | 0.040 |
Why?
|
| Prevalence | 1 | 2019 | 26 | 0.040 |
Why?
|
| Hygiene | 1 | 2019 | 1 | 0.040 |
Why?
|
| Disease Transmission, Infectious | 1 | 2019 | 1 | 0.040 |
Why?
|
| Carrier State | 1 | 2019 | 3 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 9 | 0.040 |
Why?
|
| Comorbidity | 1 | 2019 | 27 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 69 | 0.040 |
Why?
|
| Asphyxia Neonatorum | 1 | 1984 | 1 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 1984 | 11 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1984 | 9 | 0.010 |
Why?
|
| Glycogen | 1 | 1984 | 1 | 0.000 |
Why?
|
| Lactates | 1 | 1984 | 1 | 0.000 |
Why?
|
| Pyruvates | 1 | 1984 | 1 | 0.000 |
Why?
|
| Catecholamines | 1 | 1984 | 2 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1984 | 6 | 0.000 |
Why?
|
| Liver | 1 | 1984 | 4 | 0.000 |
Why?
|
| Insulin | 1 | 1984 | 7 | 0.000 |
Why?
|
| Glucagon | 1 | 1984 | 3 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1984 | 57 | 0.000 |
Why?
|
| Rats | 1 | 1984 | 159 | 0.000 |
Why?
|
| Animals | 1 | 1984 | 748 | 0.000 |
Why?
|